WASHINGTON  Federal health officials say the pain reliever in Aleve may be safer on the heart than other popular antiinflammatory drugs taken by millions of Americans A Food and Drug Administration review posted online Tuesday said naproxen  the key ingredient in Aleve and dozens of other generic pain pills  may have a lower risk of heart attack and stroke than rival medications like ibuprofen sold as Advil and Motrin FDA staffers recommend relabeling naproxen to emphasize its safety  The safety review was prompted by a huge analysis published last year that looked at  patients taking various pain relievers The findings suggest naproxen does not carry the same heart risks as other medications in the class known as nonsteroidal antiinflammatory drugs or NSAIDs  The agency released its memo ahead of a public meeting next month where outside experts will discuss the new data and whether naproxen should be relabeled The agency is not required to follow the groups advice though it often does  If ultimately implemented the labeling changes could reshape the multibilliondollar market for drugs used to treat headaches muscle pain and arthritis  The change could make Aleve and other naproxen drugs the first choice for patients with a higher risk for heart problems according to Ira Loss a pharmaceutical analyst with Washington Analysis But he added that all NSAIDs will continue to carry warnings about internal bleeding and ulceration a serious side effect that is blamed for more than  hospital visits every year